Literature DB >> 1131824

Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.

T H Corbett, D P Griswold, J G Mayo, W R Laster, F M Schabel.   

Abstract

The two-drug combination of cyclophosphamide plus adriamycin was found to be therapeutically potentiating against four different C3H mammary tumor lines, the B16 melanoma, the Ridgway osteogenic sarcoma, and the P388 leukemia. The potentiation was not schedule dependent.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1131824

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 2.  [Short-term induction and cyclic maintenance therapy in inoperable small cell bronchial cancer].

Authors:  N Niederle; W Krischke; U Schulz; C G Schmidt; S Seeber
Journal:  Klin Wochenschr       Date:  1982-08-16

Review 3.  Chemotherapy of advanced non-small cell lung cancer. A review.

Authors:  B J Takasugi; T P Miller
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging.

Authors:  Marijke De Saint-Hubert; Huijun Wang; Ellen Devos; Kathleen Vunckx; Lin Zhou; Chris Reutelingsperger; Alfons Verbruggen; Luc Mortelmans; Yicheng Ni; Felix M Mottaghy
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

5.  A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.

Authors:  R V Smalley; J Lefante; A Bartolucci; J Carpenter; C Vogel; S Krauss
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

6.  Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

Authors:  N Hartman; P J Basseches; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

7.  CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver.

Authors:  E Guillemot; B Karimdjee-Soilihi; E Pradelli; M Benchetrit; E Goguet-Surmenian; M-A Millet; F Larbret; J-F Michiels; D Birnbaum; P Alemanno; H Schmid-Antomarchi; A Schmid-Alliana
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

8.  Proceedings: The nitrosation of food amines under stomach conditions.

Authors:  C S Dyke; C L Walters
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

9.  Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.

Authors:  J S Tobias; L M Parker; M H Tattersall; E Frei
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

10.  Gamma Tocopherol Reduced Chemotherapeutic-Induced ROS in an Ovarian Granulosa Cell Line, But Not in Breast Cancer Cell Lines In Vitro.

Authors:  Daniela Figueroa Gonzalez; Fiona Young
Journal:  Antioxidants (Basel)       Date:  2020-01-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.